Corrigendum: Pharmacoeconomic Comparison of Aripiprazole Once-Monthly and Paliperidone Palmitate From a Head-To-Head Clinical Trial in Schizophrenia: A US Analysis

Drugs in Context - United Kingdom
doi 10.7573/dic.212504
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BioExcel

Related search

Real-World Analysis of Switching Patients With Schizophrenia From Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate

Drugs - Real World Outcomes
Pharmacology
2019English

Relationship Between Response to Aripiprazole Once-Monthly and Paliperidone Palmitate on Work Readiness and Functioning in Schizophrenia: A Post-Hoc Analysis of the QUALIFY Study

PLoS ONE
Multidisciplinary
2017English

Aripiprazole Lauroxil Compared With Paliperidone Palmitate in Patients With Schizophrenia: An Indirect Treatment Comparison

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

A Head-To-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial

Child Psychiatry and Human Development
DevelopmentalMental HealthChild HealthEducational PsychologyPerinatologyPsychiatryPediatrics
2013English

Medical Cost-Offset of Once-Monthly Paliperidone Palmitate Monotherapy and Adjunctive Therapy in 15-Month Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Switching From Oral Atypical Antipsychotic Monotherapy to Paliperidone Palmitate Once-Monthly in Non-Acute Patients With Schizophrenia: A Prospective, Open-Label, Interventional Study

Psychopharmacology
Pharmacology
2016English

Budget Impact Analysis of Paliperidone Palmitate 3-Monthly for the Treatment of Schizophrenia in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Correction To: Effectiveness of Aripiprazole Once-Monthly in Schizophrenia Patients Pretreated With Oral Aripiprazole: A 6-Month, Real-Life Non-Interventional Study

BMC Psychiatry
PsychiatryMental Health
2018English

A Preliminary Cost Analysis of Schizophrenic Patients Stabilized on 1-Monthly Long Acting Paliperidone Palmitate (PP1M) Injection Switching to Paliperidone Palmitate 3-Monthly Formulation (PP3M) in the Public Sector of Hong Kong

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy